Inactive Instrument

Highlights Kazia Therapeutics Ltd Australian S.E.

Equities

Kazia Therapeutics Limited Reports Successful Stage 1 Completion of the EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients	05-01	CI
Kazia Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	03-27	CI
Kazia Therapeutics Limited Enters into an Exclusive Licensing Agreement Withsovargen Co., Ltd	03-21	CI
Kazia Therapeutics' Lead Drug Candidate Meets Goal of Early-Stage Study	02-21	MT
Kazia Therapeutics Limited Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint	02-21	CI
Kazia Announces Non-Binding Letter of Intent for the Proposed Granting of Rights to Develop and Commercialize Paxalisib Outside of Oncology	11-29	CI
Kazia Therapeutics Signs Letter of Intent for Rights Licensing Deal	11-29	MT
Kazia Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/08/23	CI

No results for this search